Clinical Characteristics, Outcomes and Quality of Life in Patients With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab After Prior Chemotherapy as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
Clinical Characteristics, Outcomes and Quality of Life in Patients With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab After Prior Chemotherapy as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program. Participant who are eligible, provide consent and enroll into the squamous cell oesophageal cancer EAMS to receive Nivolumab will be included in this study.
Inclusion Criteria:
Exclusion Criteria:
• Does not receive at least one dose of nivolumab as part of the EAMS
Other protocol-defined inclusion/exclusion criteria apply
Devon, EX2 5DW, United Kingdom
Pembrokeshire, SA61 2PZ, United Kingdom
Surrey, GU2 7XX, United Kingdom
Surrey, SM2 5PT, United Kingdom